Taro rejects Sun Pharma offer

Thursday, July 19, 2012 02:25 PM

The special committee of the board of directors of Taro Pharmaceutical Industries unanimously rejected the Oct. 18, 2011, unsolicited, non-binding offer from Sun Pharmaceutical Industries—to purchase all of the issued and outstanding shares of Taro not currently held by Sun Pharma for $24.50 per share—as inadequate and not in the best interests of Taro's minority shareholders.

The special committee reached its conclusion after careful consideration, including a thorough review of Taro's business and prospects with its independent financial advisor legal counsel.

 

Share:          
CWWeekly

May 26

inVentiv Health aims to help sponsors prepare for new E.U. regulations on observational studies

ACRP partners with CRO Analytics to measure investigative sites' views of clinical trial quality

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

May

Job satisfaction mixed as workload increases
Salaries not keeping pace with rise in work, responsibilities

Gamification moving from early science to patient use
Pharma looking to use games for early diagnosis, recruitment, adherence

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs